Sanofi (NASDAQ:SNY) Downgraded by Bank of America to “Neutral”

Bank of America downgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a neutral rating in a report issued on Thursday, MarketBeat.com reports.

SNY has been the topic of a number of other research reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. TD Cowen reissued a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Citigroup began coverage on shares of Sanofi in a research note on Tuesday, January 27th. They issued a “neutral” rating for the company. Finally, Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Five research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $62.67.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $47.03 on Thursday. The firm has a market cap of $114.71 billion, a price-to-earnings ratio of 13.06, a P/E/G ratio of 1.28 and a beta of 0.45. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company has a current ratio of 1.09, a quick ratio of 0.29 and a debt-to-equity ratio of 0.20. The business has a fifty day simple moving average of $47.80 and a 200 day simple moving average of $48.62.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SNY. Brighton Jones LLC boosted its holdings in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares during the period. AQR Capital Management LLC lifted its position in shares of Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares during the period. Sivia Capital Partners LLC boosted its stake in Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares during the period. Finally, Ameritas Advisory Services LLC acquired a new stake in Sanofi in the 2nd quarter valued at approximately $28,000. Institutional investors own 14.03% of the company’s stock.

Key Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi completed its acquisition of Dynavax, strengthening its adult vaccine portfolio (adds CpG-adjuvant technology and vaccine candidates that could boost medium‑term commercial and pipeline prospects). Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi’s board named Belén Garijo as CEO in a formal appointment/press release — markets will be watching her near-term communications, strategy priorities and any shifts in R&D or capital allocation. Who is Sanofi’s new CEO Belén Garijo?
• Neutral Sentiment: Trading activity is elevated (roughly 10.8M shares vs ~4.2M average), indicating heavy repositioning; elevated volume can amplify volatility while investors digest corporate governance and strategy signals. Sanofi downgrade note
• Negative Sentiment: The board’s decision not to renew Paul Hudson’s mandate was widely reported as an abrupt ouster, creating headline-driven uncertainty about leadership stability and execution risk — selling pressure followed those reports. Sanofi tumbles after board shockingly ousts CEO Paul Hudson
• Negative Sentiment: Bank of America downgraded Sanofi from Buy to Neutral, which can reduce buy-side conviction and remove a source of upward price support in the near term. Sanofi downgraded by Bank of America

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.